Schizophrenia & Psychotic Disorders

As many as one-quarter of suicide attempts are associated with psychotic experiences, according to a systematic review and meta-analysis published online in JAMA Psychiatry.


An analysis by the FDA was prompted by a number of reports of serious adverse events and deaths with Nuplazid (pimavanserin).

When mothers used cannabis during the first 12 years of a child's life, there was a 40% higher likelihood the kid would start using the drug earlier than peers whose moms weren't using, researchers reported.

In a group of young people at high risk of psychosis, a single dose of cannabidiol reduced brain function abnormalities in regions implicated in psychosis, according to a study in JAMA Psychiatry.

Women with serious mental illness who give birth face about a 30% risk of relapse in the first three months postpartum, according to a new study.

British scientists have unraveled how a non-intoxicating component of cannabis acts in key brain areas to reduce abnormal activity in patients at risk of psychosis, suggesting the ingredient could become a novel anti-psychotic medicine.



Roger McIntyre, MD, FRCPC; Dao Thai-Cuarto, PharmD; Joshua Burke, MS; Scott Siegert, PharmD; Dimitri Grigoriadis, PhD
Joseph McEvoy, MD; Benjamin Carroll, PharmD; Sanjay Gandhi, PhD; Avery Rizio, PhD; Stephen Maher, PhD; Mark Kosinski, MA; Jakob Bjorner, MD, PhD
Stewart Factor, DO; Karen Anderson, MD; Mat Davis, PhD; Robert Hauser, MD, MBA; Lars Jarskog, MD; Joohi Jimenez-Shahed, MD; Rajeev Kumar, MD, FRCPC; Stanislaw Ochudlo, MD, PhD; William Ondo, MD; Hubert Fernandez, MD



Rajiv Tandon, MD is a member of the DSM-5 workgroup for Psychotic Disorders. In the video, he discusses the changes to this chapter in the DSM-5 and how this will impact clinical practice and treatment of patients.  

Charles Raison, MD, comments on a recent Lancet study detailing how five major psychiatric disorders—autism, ADHD, bipolar disorder, major depressive disorder, and schizophrenia—are genetically connected.

Leslie Citrome, MD, MPH, Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College, highlights what recent research shows regarding the role of glutamate in schizophrenia.